Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
4 hedge funds and large institutions have $921K invested in Sonnet BioTherapeutics in 2020 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
1,819% more capital invested
Capital invested by funds: $48K → $921K (+$873K)
300% more funds holding
Funds holding: 1 → 4 (+3)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.14M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$23.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$23.3K |
| 4 |
RFA
Reilly Financial Advisors
La Mesa,
California
|
+$11.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Truist Financial
Charlotte,
North Carolina
|
-$15K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9K |
| 3 |
ECM
ETrade Capital Management
Arlington,
Virginia
|
-$7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
BlackRock
New York
| $881K | +$1.14M | +98 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $16K | +$23.3K | +2 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $16K | +$23.3K | +2 | New |
|
|
RFA
4
Reilly Financial Advisors
La Mesa,
California
| $8K | +$11.6K | +1 | New |
|
|
5
Truist Financial
Charlotte,
North Carolina
| – | -$15K | -1 | Closed |
|
|
ECM
6
ETrade Capital Management
Arlington,
Virginia
| – | -$7K | – | – |
|
|
7
Northern Trust
Chicago,
Illinois
| – | -$4K | – | – |
|
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$7K | – | – |
|
|
9
Vanguard Group
Malvern,
Pennsylvania
| – | -$9K | – | – |
|
SONN Hedge Fund Activity: Q2 2020 in Review
4 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q2 2020, worth a combined $921K — up 1,819% from $48K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SONN positions and 1 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $1.14M. The largest seller was Truist Financial, exiting entirely with an estimated $15K sold.
- 4 institutional investors held Sonnet BioTherapeutics (SONN) as of Q2 2020, up from 1 in Q1 2020.
- Funds reported $921K of Sonnet BioTherapeutics stock for Q2 2020, up 1,819% quarter-over-quarter.
- 4 funds opened new Sonnet BioTherapeutics positions in Q2 2020 and 1 closed out, a net change of +3 holders.
- The largest Sonnet BioTherapeutics buyer in Q2 2020 was BlackRock, an estimated $1.14M added.
- The largest Sonnet BioTherapeutics seller in Q2 2020 was Truist Financial, an estimated $15K sold.
Based on aggregated 13F filings for Q2 2020.